United States
Torrent Pharma Inc. (TPI) is a 100% US subsidiary of Torrent Pharmaceuticals Ltd., a prominent pharmaceuticals company from India. Established in 2004, TPI has carved a significant niche in the US generics market with 64 FDA approved products.
Notably, TPI boasts market shares of 10-30% in several categories, with 14 products ranking within the top three positions. This prowess in market penetration underscores the company's strategic portfolio management and competitiveness in the generics domain.
Looking ahead, TPI projects substantial growth in the US market, supported by a robust pipeline of Abbreviated New Drug Applications (ANDAs) and expansion of its manufacturing capabilities in India. As the company continues to leverage its parent company's expertise, its trajectory seems promising for investors seeking exposure in the pharmaceuticals industry.
Incorporating diversity as an equal opportunity employer further enhances TPI's commendable reputation within the business community.
